MedImmune gets OK from China to pursue arthritis drug in joint venture deal
Gaithersburg-based MedImmune is expanding its footprint in China's drug market after receiving a permit to begin clinical trials there on a biologic therapy for rheumatoid arthritis.
MedImmune, which is the R&D arm for London-based AstraZeneca (NYSE: AZN) drug giant AstraZeneca, produced the biologic in a joint venture with leading Chinese biologics manufacturer WuXi AppTech.
This is the first collaboration of its kind between an multinational pharmaceutical corporation and a Chinese company, said…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Tina Reed Source Type: news
More News: American Health | Arthritis | AstraZeneca | Clinical Trials | Health Management | Rheumatoid Arthritis | Rheumatology